Seelos therapeutics announces its inclusion in the first u.s. listed exchange traded fund (etf) focused on psychedelics

New york, june 1, 2021 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today that it has been included in the defiance next gen altered experience etf, the first u.s. listed exchange traded fund (etf) focused on psychedelics which began trading on friday, may 28 th on the new york stock exchange under the symbol psy. seelos' inclusion is based on its lead program sls-002 (intranasal racemic ketamine), which recently released positive top-line data from part 1, the open-label cohort, of its potentially registrational proof-of-concept study for acute suicidal ideation and behavior (asib) in patients with major depressive disorder (mdd).
SEEL Ratings Summary
SEEL Quant Ranking